Extracorporeal life support, or ECLS, has become a central technology in advanced cardiopulmonary support, and with that growth has come a surge of innovation in blood pumps, membrane lungs, cannulae, tubing systems, and other circuit components. This article, published as a guideline, focuses on a major problem in the field: many novel devices are still evaluated in early-stage laboratory settings using methods that differ substantially from one research group to another. That lack of consistency makes it hard to compare performance data, difficult to judge scientific quality, and challenging to translate promising results into real-world clinical development. The authors therefore propose a standardized framework for in-vitro evaluation of ECLS devices, grounded in international norms and intended to improve reproducibility, comparability, and reporting quality across the field.
The article’s central message is that standardized in-vitro testing should become normal practice in ECLS research and development. The authors explain that laboratory testing and in-vivo testing serve different purposes. In-vitro work is meant to provide controlled, repeatable evaluation under defined operating points, while in-vivo testing is shaped by physiology and therefore cannot be fully standardized. Because of that distinction, laboratory studies are the right place to establish a shared language of methods, measurements, and reporting. Standardization lets researchers compare new devices not only with each other, but also with commercially available systems and with devices of different sizes or intended populations, as long as outcomes are reported in broadly comparable units.
A major strength of the paper is that it translates existing ISO standards into practical guidance for research groups. The authors note that standards used for market approval already define what to test, how long to test, when to collect samples, which fluids to use, and how to structure parts of the test setup. They argue that these standards are not only for industry; they are also highly useful in academic and preclinical research. Some commercial requirements, such as packaging or instructions-for-use details, may be less relevant in very early development, but the core methodological principles still apply. When a novel device genuinely requires deviation from a standard method, the paper says that the deviation should be clearly justified and minimized as much as possible.
The guideline then moves into specific device categories. For cannulae, it references ISO 18193 and emphasizes reporting of geometry, material properties, side-hole configuration, flow and pressure probe placement, and tests such as pressure drop, flow characterization, recirculation in dual-lumen designs, and blood cell damage. For blood pumps, it highlights hydraulic performance, priming volume, durability, and blood trauma. Pump performance curves should be presented across operating ranges so readers can understand how flow and pressure head interact under realistic conditions.
For membrane lungs, the paper points to ISO 7199 and identifies four especially important elements: gas exchange performance, priming volume, pressure drop, and blood cell damage. The authors explain that gas exchange testing should be performed with whole blood because most oxygen is carried by hemoglobin, not simply dissolved in plasma. They also explain why parameters like temperature, pH, and carbon dioxide tension matter, since these affect the oxygen dissociation curve and therefore influence how oxygen transfer should be interpreted. This makes the article valuable not only as a checklist, but also as a technical explainer of why proper test control matters in oxygenator research.
The article also spends substantial attention on blood cell damage and hemolysis testing. It recommends tightly controlled circuit conditions, minimal circuit volume, standardized temperature, specified blood parameters, and repeated testing using blood from different donors. The total test duration for these evaluations is described as 6 hours, with defined sampling schedules and repeated runs to account for variability in blood response. Important measurements include plasma free hemoglobin, white blood cells, platelets, blood gases, hemoglobin or hematocrit, activated clotting time, flow rates, pressures, circuit volume change, and temperature. By setting these expectations, the guideline helps transform isolated bench experiments into more interpretable and comparable preclinical evidence.
Another important contribution is the discussion of thrombogenicity testing. The authors acknowledge that current standards for ECLS components do not yet adequately require or standardize in-vitro thrombogenicity assessment, even though thrombosis remains a critical hemocompatibility issue. They argue that better bench methods are urgently needed because waiting until animal studies to discover thrombogenic problems is inefficient, expensive, and ethically problematic. At the same time, they are candid about the barriers, including large circuit-specific differences, signal-to-noise limitations, blood volume demands, and imperfect translation from animal blood to human coagulation biology.
The paper does not overstate what in-vitro methods can do. It clearly states that laboratory testing cannot reproduce the full inflammatory, coagulation, and disease-related complexity of living patients on ECLS. It also notes that the practical duration of in-vitro tests is limited, which makes long-term effects difficult to study. That balanced discussion strengthens the guideline because it frames standardization as a way to improve early-stage evidence, not as a replacement for animal work, clinical validation, or higher-level evidence synthesis.
From an SEO perspective, this article is especially relevant to readers searching for ECLS device testing standards, ECMO research methods, oxygenator evaluation, blood pump hemolysis testing, and hemocompatibility assessment. Its broader significance is that it creates a common framework for engineers, clinicians, reviewers, journal editors, and device developers. By promoting minimal reporting criteria and standardized methods, it aims to make ECLS research more transparent, easier to review, and more useful for evidence-based decision-making. In that sense, the article is less about one experimental result and more about upgrading the quality of the whole field’s preclinical research infrastructure.
